Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 19,000
- Avg volume
- 45,078
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 100%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Bi...
Show more
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 612 961 5656
- Website
- https://www.nascentbiotech.com
- Address
- 631 US Hwy 1, Suite 407, North Palm Beach, United States
Latest news
No headlines yet.
